T. Rowe Price Associates
NUVL

T. Rowe Price Associates’s Nuvalent NUVL Stock Holding History

T. Rowe Price Associates’s Portfolio NUVL Stock Details NUVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$211M Sell
2,056,133
-90,805
-4% -$9.25M 0.02% 451
2025
Q4 		$216M Buy
2,146,938
+336,518
+19% +$33.2M 0.02% 441
2025
Q3 		$157M Buy
1,810,420
+15,047
+0.8% +$1.19M 0.02% 515
2025
Q2 		$137M Buy
1,795,373
+344,771
+24% +$25.2M 0.02% 505
2025
Q1 		$103M Buy
1,450,602
+152,692
+12% +$11.9M 0.01% 546
2024
Q4 		$102M Buy
1,297,910
+215,633
+20% +$20.1M 0.01% 563
2024
Q3 		$111M Buy
1,082,277
+328,139
+44% +$27.2M 0.01% 545
2024
Q2 		$57.2M Sell
754,138
-104,023
-12% -$7.4M 0.01% 682
2024
Q1 		$64.4M Sell
858,161
-248,221
-22% -$19.8M 0.01% 654
2023
Q4 		$81.4M Buy
1,106,382
+299,446
+37% +$18.5M 0.01% 585
2023
Q3 		$37.1M Buy
806,936
+231,258
+40% +$10.3M 0.01% 768
2023
Q2 		$24.3M Sell
575,678
-11,182
-2% -$423K ﹤0.01% 887
2023
Q1 		$15.3M Buy
586,860
+51,174
+10% +$1.51M ﹤0.01% 982
2022
Q4 		$16M Buy
+535,686
New +$14.9M ﹤0.01% 972

Other funds holding NUVL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's NUVL Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Nuvalent (NUVL) stake by 4.2% in Q1 2026, selling an estimated $9.25M and leaving 2,056,133 shares worth $211M. The position accounts for 0.02% of the portfolio, ranked #451.

T. Rowe Price Associates first reported a position in NUVL in Q4 2022 and has held it in 14 quarters since. The position peaked at $216M in Q4 2025. 263 funds tracked by Wall St. Rank hold NUVL as of Q1 2026.

  • T. Rowe Price Associates held 2,056,133 shares of Nuvalent worth $211M as of Q1 2026.
  • T. Rowe Price Associates sold 90,805 Nuvalent shares in Q1 2026, an estimated $9.25M.
  • Nuvalent made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #451 holding.
  • T. Rowe Price Associates first reported a position in Nuvalent in Q4 2022 and has held it in 14 quarters since.
  • T. Rowe Price Associates's Nuvalent position peaked at $216M in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Nuvalent as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.